ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Sevilla, AN, ESP:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Sevilla, Spain and 145 other locations

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood s...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Dexamethasone
Drug: Melphalan

Phase 2

PETHEMA Foundation

Sevilla, Spain and 15 other locations

after Intensification therapy) and safety of Tec-Dara (Teclistamab+Daratumumab) and Tal-Dara (Talquetamab+Daratumumab) in de novo high-risk multiple...

Enrolling
High-Risk de Novo Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

PETHEMA Foundation

Sevilla, Spain and 9 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Sevilla, Spain and 126 other locations

(Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple...

Enrolling
Multiple Myeloma
Drug: Dexamethasone
Drug: Bortezomib

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Sevilla, Spain and 129 other locations

dexamethasone) in newly diagnosed (ND) transplant eligible multiple myeloma (MM) patients.Eligible patients will be included in the...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Dexamethasone

Phase 2

PETHEMA Foundation

Sevilla, Andalucia, Spain and 17 other locations

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose o...

Enrolling
Relapsed/Refractory Multiple Myeloma
Drug: Daratumumab
Drug: Nirogacestat

Phase 1

TeneoOne

Sevilla, Spain and 48 other locations

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Sevilla, Spain and 180 other locations

antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratum ...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

Phase 3

Pfizer
Pfizer

Sevilla, Spain and 270 other locations

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Sevilla, Spain and 135 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems